Home › Quarterly results › Pharmaceuticals
Pharmaceuticals: Q1 FY27 results (April-June 2026)
106 companies have declared Pharmaceuticals Q1 FY27 results so far, the latest on 21 Sep 2026.
Across the 99 non-financial companies with a year-ago quarter to compare, sales grew +13.6% and net profit +7.6% year on year, and the combined operating margin narrowed 144 bps to 21.6%.
68% of companies grew net profit; 5 turned a loss into a profit; 47% beat their own profit trend and 40% fell short of it.
Latest results
Results calendar
Q2 FY27 Q1 FY27 Q4 FY26 Q3 FY26 Q2 FY26
Pharmaceuticals Q1 FY27 scoreboard
Sales growth
+13.6%
YoY, 99 companies combined; median +17.0%
Net profit growth
+7.6%
YoY combined; median +26.1%
Operating margin
21.6%
-144 bps YoY
Grew profit
68%
5 turnarounds, 4 into loss
Vs own profit trend
47% / 40%
above / below, 13% in line
Price since results
-2.1%
median; 46% of 98 stocks up
Other-income heavy
24
25%+ of pre-tax profit from other income & one-offs
Latest Pharmaceuticals Q1 FY27 results 106
Page 3 of 4
Tap ☆ on any company to add it to My companies. Your list stays in this browser.
M Cap ₹5,375 Cr
P/E 18.4
PEG 1.15
Since results -16.5%
Profit +23% above its own trend 27% of pre-tax profit came from other income and one-off items
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+3.0% +14.1%
668 585 648 Operating profit
+2.1% +34.9%
143 106 140 OPM %
-19 bps +330 bps
21.4% 18.1% 21.6% Other income
+32.4% -4.7%
47.7 50.0 36.0 Net profit
+9.5% +28.6%
132 103 121 PAT margin %
+117 bps +224 bps
19.8% 17.6% 18.7% EPS (₹)
+9.3% +28.2%
8.14 6.35 7.45
Quality of profit
Pre-tax profit ₹175 Cr: core business ₹127 Cr, other income ₹47.7 Cr.
Core profit YoY: +2.5%
· reported profit +9.5%
Cash & debt
FY26 cash from operations ₹200 Cr:
71% of FY26 net profit of ₹280 Cr.
Borrowings ₹15.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹654 ₹668
+2.1% in line Net profit ₹107 ₹132
+23.5% above
AI read of the filing ₹132 Cr Q1 Profit: FDC Reports 9% YoY Growth and Green Energy Investment Positive Consolidated Revenue from operations grew to ₹715.35 cr in Q1 FY27 from ₹683.91 cr in Q1 FY26. Net Profit for the quarter increased to ₹132.39 cr, up 9.1% from ₹121.35 cr in the same period last year. Earnings Per Share (EPS) rose to ₹8.14 from ₹7.45 YoY. Full analysis →
M Cap ₹19,983 Cr
P/E 67.2
PEG 0.62
Since results +60.4%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+44.9% +6.6%
466 437 321 Operating profit
+48.7% +13.5%
136 120 91.6 OPM %
+75 bps +179 bps
29.3% 27.5% 28.5% Other income
-50.9% -93.0%
3.1 45.0 6.4 Net profit
+115.2% -6.6%
101 108 46.9 PAT margin %
+707 bps -306 bps
21.7% 24.7% 14.6% EPS (₹)
+7.7% -6.4%
5.16 5.51 4.79
Quality of profit
Pre-tax profit ₹98.1 Cr: core business ₹89.0 Cr, other income ₹3.1 Cr, exceptional & other items ₹6.0 Cr.
Core profit YoY: +102.5%
· reported profit +115.2%
Cash & debt
FY26 cash from operations ₹342 Cr:
140% of FY26 net profit of ₹243 Cr.
Borrowings ₹660 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹419 ₹466
+11.3% above Net profit ₹93.8 ₹101
+7.6% in line
AI read of the filing Shilpa Medicare Q1 PAT Jumps 115% YoY to ₹100.9 Cr; EUR 7M Investment in Gate2Brain Positive Consolidated Revenue increased 44.9% YoY to ₹465.78 Cr from ₹321.46 Cr in the year-ago period. Net Profit (PAT) surged 115% YoY to ₹100.88 Cr compared to ₹46.89 Cr in Q1 FY26. Strategic investment of up to EUR 7 million (~₹64 Cr) committed to Gate2Brain via subsidiary Shilpa Biocare. Full analysis →
M Cap ₹123 Cr
P/E 50.8
PEG —
Since results -6.4%
Profit +795% above its own trend Operating cash flow was negative in FY26 despite a profit
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+14.1% +14.1%
80.7 70.7 70.7 Operating profit
+12.1% —
4.7 0.1 4.2 OPM %
-10 bps +561 bps
5.8% 0.2% 5.9% Other income
loss narrowed to loss -1.0 2.9 -1.8 Net profit
+347.4% +112.7%
1.3 0.6 0.3 PAT margin %
+120 bps +75 bps
1.6% 0.9% 0.4% EPS (₹)
+380.0% +118.2%
0.24 0.11 0.05
Quality of profit
Pre-tax profit ₹2.1 Cr: core business ₹3.1 Cr, other income −₹1.0 Cr.
Core profit YoY: +14.6%
· reported profit +347.4%
Cash & debt
FY26 cash from operations −₹4.0 Cr:
-282% of FY26 net profit of ₹1.4 Cr.
Borrowings ₹58.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹67.8 ₹80.7
+19.0% above Net profit ₹0.1 ₹1.3
+794.8% above
AI read of the filing Balaxi Pharma Q1 Revenue Rs 80.68 Cr; Jadcherla Plant Starts Commercial Production Watch Consolidated revenue grew to Rs 80.68 Cr in Q1 FY27 from Rs 70.74 Cr in the same quarter last year. Jadcherla facility commenced production with Paracetamol 500mg and Piroxicam 20mg. Total approved commercial product portfolio expanded to 31 products after receiving 29 new permissions. Full analysis →
M Cap ₹473 Cr
P/E 31.0
PEG —
Since results +0.0%
Profit -58% below its own trend Operating margin contracted 169 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
-11.6% -2.9%
72.9 75.1 82.5 Operating profit
-22.1% +119.2%
9.1 4.2 11.7 OPM %
-169 bps +697 bps
12.5% 5.5% 14.2% Other income
-53.5% -77.0%
0.5 2.0 1.0 Net profit
-58.0% +425.8%
1.8 0.3 4.4 PAT margin %
-279 bps +206 bps
2.5% 0.5% 5.3% EPS (₹)
-36.4% +499.3%
8.75 1.46 13.75
Quality of profit
Pre-tax profit ₹3.4 Cr: core business ₹3.0 Cr, other income ₹0.5 Cr.
Core profit YoY: -50.6%
· reported profit -58.0%
Against its own trend ?
Trend Actual Gap
Sales ₹79.6 ₹72.9
-8.3% below Net profit ₹4.4 ₹1.8
-57.7% below
AI read of the filing Haleos Labs Q1 FY27: Net Profit Drops 36% YoY to ₹2.65 Cr on 11.6% Revenue Decline Negative Consolidated Revenue from Operations fell 11.6% YoY to ₹72.94 Cr from ₹82.50 Cr. Net Profit attributable to the parent decreased 36.3% YoY to ₹2.65 Cr from ₹4.16 Cr. Consolidated EPS for the quarter stood at ₹8.75, down from ₹13.75 in Q1 FY26. Full analysis →
M Cap ₹6,783 Cr
P/E 20.9
PEG —
Since results -13.6%
Profit +39% above its own trend Operating margin expanded 294 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+7.8% -7.3%
438 472 406 Operating profit
+21.4% -19.4%
115 143 95.0 OPM %
+294 bps -395 bps
26.3% 30.3% 23.4% Other income
-31.1% +55.0%
6.2 4.0 9.0 Net profit
+19.3% -18.9%
83.5 103 70.0 PAT margin %
+184 bps -275 bps
19.1% 21.8% 17.2% EPS (₹)
+20.0% -18.7%
36.26 44.61 30.22
Quality of profit
Pre-tax profit ₹112 Cr: core business ₹106 Cr, other income ₹6.2 Cr.
Core profit YoY: +23.4%
· reported profit +19.3%
Against its own trend ?
Trend Actual Gap
Sales ₹358 ₹438
+22.4% above Net profit ₹60.1 ₹83.5
+39.0% above
AI read of the filing 19% PBT Growth in Q2 2026; Sanofi India Reports 14% Insulin Portfolio Growth Positive Profit Before Tax (PBT) increased 19% to ₹112 crore from ₹94 crore in Q2 2025 Insulin portfolio (Lantus, Toujeo, Apidra) delivered 14% growth for the second consecutive quarter Public sector business accelerated by 70% through the CARE Accounts initiative Full analysis →
M Cap ₹11,863 Cr
P/E 64.3
PEG —
Since results +18.6%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+26.6% -13.0%
158 182 125 Operating profit
+24.8% -12.8%
54.9 63.0 44.0 OPM %
-51 bps +8 bps
34.7% 34.6% 35.2% Other income
+8.9% -9.2%
5.4 6.0 5.0 Net profit
+30.9% -17.2%
40.6 49.0 31.0 PAT margin %
+84 bps -128 bps
25.6% 26.9% 24.8% EPS (₹)
+13.2% -17.1%
3.59 4.33 3.17
Quality of profit
Pre-tax profit ₹54.3 Cr: core business ₹48.8 Cr, other income ₹5.4 Cr.
Core profit YoY: +25.2%
· reported profit +30.9%
AI read of the filing 29.8% YoY PAT Growth in Q1 FY27; Revenue Reaches ₹158.27 Cr Positive Consolidated Revenue from operations increased 26.7% YoY to ₹158.27 cr from ₹124.92 cr. Net Profit for the quarter rose to ₹40.59 cr, a 29.8% increase compared to ₹31.27 cr in Q1 FY26. Unutilized IPO proceeds stand at ₹75.46 cr as of June 30, 2026, primarily earmarked for Nandesari facility machinery. Full analysis →
M Cap ₹15,744 Cr
P/E 22.8
PEG 0.81
Since results -2.1%
Operating margin contracted 101 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+25.7% +16.3%
2,150 1,848 1,711 Operating profit
+18.0% +45.6%
332 228 281 OPM %
-101 bps +310 bps
15.4% 12.3% 16.4% Other income
+129.7% +646.5%
14.9 2.0 6.5 Net profit
+12.7% -14.3%
173 202 154 PAT margin %
-93 bps -288 bps
8.1% 10.9% 9.0% EPS (₹)
+12.1% -14.6%
8.80 10.31 7.85
Quality of profit
Pre-tax profit ₹222 Cr: core business ₹207 Cr, other income ₹14.9 Cr.
Core profit YoY: +12.2%
· reported profit +12.7%
Cash & debt
FY26 cash from operations ₹783 Cr:
116% of FY26 net profit of ₹672 Cr.
Borrowings ₹1,430 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹1,885 ₹2,150
+14.1% above Net profit ₹180 ₹173
-3.9% in line
AI read of the filing ₹2,150 Cr Revenue: Alembic Pharma Reports 25.6% YoY Revenue Growth in Q1 FY27 Positive Consolidated revenue from operations grew 25.6% YoY to ₹2,149.77 cr from ₹1,710.72 cr. Net profit after non-controlling interests rose 13.6% YoY to ₹175.33 cr. Operating margin (EBITDA) stood at 13.84%, a decline from 16.18% in Q1 FY26. Full analysis →
M Cap ₹7,099 Cr
P/E 50.2
PEG 2.09
Since results +122.9%
Profit +438% above its own trend Operating margin expanded 879 bps YoY Core business grew faster than reported profit (core profit +524%) FY26 operating cash flow was only 34% of profit
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+34.1% +17.6%
570 485 425 Operating profit
+241.5% +243.9%
82.5 24.0 24.2 OPM %
+879 bps +953 bps
14.5% 4.9% 5.7% Other income
+17.6% -35.2%
5.2 8.0 4.4 Net profit
+394.0% +252.2%
56.3 16.0 11.4 PAT margin %
+720 bps +658 bps
9.9% 3.3% 2.7% EPS (₹)
+415.0% +255.2%
1.03 0.29 0.20
Quality of profit
Pre-tax profit ₹74.5 Cr: core business ₹69.3 Cr, other income ₹5.2 Cr.
Core profit YoY: +524.3%
· reported profit +394.0%
Cash & debt
FY26 cash from operations ₹33.0 Cr:
34% of FY26 net profit of ₹96.5 Cr.
Borrowings ₹208 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹421 ₹570
+35.3% above Net profit ₹10.5 ₹56.3
+437.8% above
AI read of the filing Morepen Lab Q1 Net Profit Jumps 570% YoY to ₹53.99 Cr; Medical Device Hive-off Timeline Extended Positive Consolidated Net Profit increased by 569.8% YoY to ₹53.99 Cr in Q1 FY27 Total Income for the quarter rose 38.2% to ₹546.35 Cr compared to ₹395.38 Cr in Q1 FY26 Basic EPS improved significantly to ₹0.99 from ₹0.15 in the year-ago period Full analysis →
M Cap ₹43,034 Cr
P/E 40.3
PEG 2.24
Since results -4.7%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+16.6% -5.7%
938 995 805 Operating profit
+17.6% -15.8%
296 351 251 OPM %
+29 bps -379 bps
31.5% 35.3% 31.2% Other income
+0.1% +21.6%
43.8 36.0 43.7 Net profit
+15.7% -14.7%
237 278 205 PAT margin %
-19 bps -267 bps
25.3% 27.9% 25.5%
Quality of profit
Pre-tax profit ₹322 Cr: core business ₹279 Cr, other income ₹43.8 Cr.
Core profit YoY: +18.5%
· reported profit +15.7%
Cash & debt
FY26 cash from operations ₹903 Cr:
87% of FY26 net profit of ₹1,036 Cr.
Borrowings ₹33.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹809 ₹938
+16.0% above Net profit ₹224 ₹237
+6.0% in line
AI read of the filing 15.7% YoY PAT Growth in Q1; MD Bhushan Akshikar Re-appointed for 2 Years Positive Consolidated Revenue from operations increased 16.5% YoY to ₹938.44 cr from ₹805.17 cr. Consolidated Net Profit rose 15.7% YoY to ₹237.18 cr compared to ₹205.01 cr in the year-ago period. Standalone Other Income includes a ₹18 cr dividend received from 100% subsidiary Biddle Sawyer Limited. Full analysis →
M Cap ₹8,927 Cr
P/E —
PEG —
Since results -17.1%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
-17.4% —
293 — 355 Operating profit
-18.9% —
98.1 — 121 OPM %
-65 bps —
33.5% — 34.1% Other income
+84.6% —
15.2 — 8.3 Net profit
-14.2% —
78.3 — 91.2 PAT margin %
+100 bps —
26.7% — 25.7% EPS (₹)
-14.3% —
4.51 — 5.26
Quality of profit
Pre-tax profit ₹106 Cr: core business ₹90.7 Cr, other income ₹15.2 Cr.
Core profit YoY: -20.9%
· reported profit -14.2%
AI read of the filing Blue Jet Q1 Revenue at ₹293 Cr; Dividend Record Date Set for Sept 14, 2026 Neutral Q1 FY27 Revenue from operations stood at ₹293.11 cr, down from ₹354.76 cr in the same quarter last year. Profit Before Tax for the quarter was ₹105.95 cr, compared to ₹122.86 cr in Q1 FY26. Dividend of ₹1.2 per share (60% of face value) finalized with a record date of September 14, 2026. Full analysis →
M Cap ₹2,47,948 Cr
P/E 84.8
PEG 6.52
Since results +16.5%
Profit +38% above its own trend Operating margin expanded 1050 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+27.8% +8.8%
3,080 2,831 2,410 Operating profit
+72.2% +34.4%
1,255 934 729 OPM %
+1050 bps +775 bps
40.7% 33.0% 30.2% Other income
-46.2% -58.7%
64.0 155 119 Net profit
+65.5% +20.1%
902 751 545 PAT margin %
+667 bps +276 bps
29.3% 26.5% 22.6% EPS (₹)
+65.4% +20.0%
33.95 28.29 20.53
Quality of profit
Pre-tax profit ₹1,180 Cr: core business ₹1,116 Cr, other income ₹64.0 Cr.
Core profit YoY: +81.8%
· reported profit +65.5%
Cash & debt
FY26 cash from operations ₹2,738 Cr:
107% of FY26 net profit of ₹2,568 Cr.
Borrowings ₹7.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹2,724 ₹3,080
+13.1% above Net profit ₹652 ₹902
+38.3% above
AI read of the filing 65.5% YoY PAT Growth; Divi's Labs Reports Strong Q1 FY27 Revenue of 3,080 Cr Positive Consolidated Revenue from operations grew 27.8% YoY to 3,080 Cr from 2,410 Cr. Net Profit (PAT) increased by 65.5% YoY to 902 Cr compared to 545 Cr in the previous year. Profit Before Tax (PBT) margin expanded significantly to 37.5% from 29.0% in Q1 FY26. Full analysis →
M Cap ₹3,772 Cr
P/E 19.7
PEG 3.94
Since results -2.0%
Profit -22% below its own trend Operating margin expanded 145 bps YoY Core business grew faster than reported profit (core profit +41%)
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+18.9% -2.4%
703 720 591 Operating profit
+32.7% +2.5%
98.2 95.8 74.0 OPM %
+145 bps +67 bps
14.0% 13.3% 12.5% Other income
— +6.6%
0.8 0.8 0.0 Net profit
-7.2% -9.3%
50.1 55.3 54.0 PAT margin %
-200 bps -54 bps
7.1% 7.7% 9.1% EPS (₹)
-7.1% -9.3%
5.49 6.05 5.91
Quality of profit
Pre-tax profit ₹69.2 Cr: core business ₹70.5 Cr, other income ₹0.8 Cr, exceptional & other items −₹2.1 Cr.
Core profit YoY: +41.0%
· reported profit -7.2%
Cash & debt
FY26 cash from operations ₹254 Cr:
130% of FY26 net profit of ₹195 Cr.
Borrowings ₹577 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹634 ₹703
+10.8% above Net profit ₹64.6 ₹50.1
-22.4% below
AI read of the filing Aarti Drugs Q1 FY27: Net Profit Jumps 67% YoY to ₹55.3 Cr; Revenue Up 19% Positive Consolidated Revenue grew 19% YoY to ₹702.78 Cr from ₹590.51 Cr. Net Profit increased 67.4% YoY to ₹55.26 Cr compared to ₹33.0 Cr in Q1 FY26. Calculated Operating Profit Margin improved to approximately 13.9% from the TTM average of 12.0%. Full analysis →
M Cap ₹64,714 Cr
P/E 36.0
PEG 0.47
Since results +1.0%
Profit +999% above its own trend Operating margin expanded 224 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+23.1% +6.6%
4,018 3,771 3,264 Operating profit
+38.6% +5.5%
805 763 581 OPM %
+224 bps -21 bps
20.0% 20.2% 17.8% Other income
+148.7% from loss 65.8 -184 26.4 Net profit
+927.9% +60.4%
483 301 47.0 PAT margin %
+1058 bps +403 bps
12.0% 8.0% 1.4% EPS (₹)
+930.7% +60.2%
17.11 10.68 1.66
Quality of profit
Pre-tax profit ₹643 Cr: core business ₹578 Cr, other income ₹65.8 Cr.
Core profit YoY: +47.2%
· reported profit +927.9%
Cash & debt
FY26 cash from operations ₹3,445 Cr:
253% of FY26 net profit of ₹1,362 Cr.
Borrowings ₹594 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹3,533 ₹4,018
+13.7% above Net profit ₹43.7 ₹483
+999.0% above
AI read of the filing ₹4,018 Cr Revenue: Glenmark Reports 23% YoY Growth and 60% QoQ PAT Surge in Q1 FY27 Positive Consolidated revenue from operations increased 23.1% YoY to ₹4,018.48 cr Consolidated PAT surged to ₹482.83 cr from ₹46.97 cr in Q1 FY26 Basic EPS for the quarter improved to ₹17.11 compared to ₹1.66 in the year-ago period Full analysis →
M Cap ₹14,242 Cr
P/E 52.2
PEG 13.05
Since results -3.7%
Profit +88% above its own trend Operating margin expanded 189 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+26.2% -21.0%
257 326 204 Operating profit
+34.2% -30.2%
82.4 118 61.4 OPM %
+189 bps -420 bps
32.0% 36.2% 30.1% Other income
-6.2% -14.5%
12.8 15.0 13.7 Net profit
+31.0% -34.4%
57.7 88.0 44.1 PAT margin %
+81 bps -459 bps
22.4% 27.0% 21.6% EPS (₹)
+31.1% -35.0%
5.52 8.49 4.21
Quality of profit
Pre-tax profit ₹78.3 Cr: core business ₹64.2 Cr, other income ₹12.8 Cr, exceptional & other items ₹1.3 Cr.
Core profit YoY: +47.5%
· reported profit +31.0%
Cash & debt
FY26 cash from operations ₹267 Cr:
103% of FY26 net profit of ₹259 Cr.
Borrowings ₹2.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹178 ₹257
+45.0% above Net profit ₹30.7 ₹57.7
+88.0% above
AI read of the filing Concord Biotech Q1 Results: Net Profit Up 39% YoY to ₹61.22 Cr; Revenue Grows 26% Positive Revenue from operations increased 26.2% YoY to ₹257.49 Cr from ₹203.99 Cr. Consolidated Net Profit rose 38.9% YoY to ₹61.22 Cr against ₹44.06 Cr in the previous year. Earnings Per Share (EPS) improved to ₹5.85 from ₹4.07 in the corresponding quarter last year. Full analysis →
M Cap ₹12,365 Cr
P/E 62.3
PEG —
Since results -3.5%
Operating margin expanded 187 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+21.7% +19.6%
422 353 347 Operating profit
+33.0% +50.2%
93.1 62.0 70.0 OPM %
+187 bps +448 bps
22.0% 17.6% 20.2% Other income
+57.5% -23.4%
3.1 4.1 2.0 Net profit
+30.7% +32.6%
60.1 45.3 46.0 PAT margin %
+97 bps +139 bps
14.2% 12.8% 13.3% EPS (₹)
+30.2% +32.7%
9.83 7.41 7.55
Quality of profit
Pre-tax profit ₹80.4 Cr: core business ₹77.2 Cr, other income ₹3.1 Cr.
Core profit YoY: +30.8%
· reported profit +30.7%
AI read of the filing 30.1% PAT Growth: CORONA Remedies Reports Strong Q1 FY27 Results and New Plant Inauguration Positive Revenue from operations grew 21.9% YoY to ₹422.4 Cr for the quarter ended June 30, 2026. PAT increased by 30.1% YoY to ₹60.1 Cr, with PAT margins improving by 90 bps to 14.2%. EBITDA margins expanded significantly by 190 bps to reach 22.0% compared to 20.1% in Q1FY26. Full analysis →
M Cap ₹4,164 Cr
P/E 40.8
PEG 0.26
Since results +18.4%
Profit -33% below its own trend
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+5.6% -13.0%
207 238 196 Operating profit
+4.0% +2.4%
41.0 40.0 39.4 OPM %
-30 bps +298 bps
19.8% 16.8% 20.1% Other income
+194.1% -41.9%
1.7 3.0 0.6 Net profit
-1.4% -38.8%
20.2 33.0 20.5 PAT margin %
-69 bps -410 bps
9.8% 13.9% 10.5% EPS (₹)
-3.5% -36.1%
2.23 3.49 2.31
Quality of profit
Pre-tax profit ₹27.2 Cr: core business ₹25.5 Cr, other income ₹1.7 Cr.
Core profit YoY: +7.1%
· reported profit -1.4%
Cash & debt
FY26 cash from operations ₹59.0 Cr:
58% of FY26 net profit of ₹102 Cr.
Borrowings ₹365 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹236 ₹207
-12.2% below Net profit ₹30.1 ₹20.2
-32.9% below
AI read of the filing SMSPHARMA Q1 Net Profit Up 16% YoY to ₹21.1 Cr; ₹50 Cr Loan to Subsidiary Approved Neutral Standalone Net Profit grew 16% YoY to ₹21.13 crore for the quarter ended June 30, 2026 Consolidated Revenue from Operations stood at ₹206.96 crore, a 5.5% increase over Q1 FY26 Approved an unsecured loan of up to ₹50 crore to subsidiary SMS Peptides Private Limited for business purposes Full analysis →
M Cap ₹4,22,283 Cr
P/E 34.9
PEG 2.68
Since results -12.2%
Profit +16% above its own trend Operating margin contracted 218 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+10.5% +4.7%
15,300 14,612 13,851 Operating profit
+2.7% +11.7%
4,418 3,954 4,302 OPM %
-218 bps +181 bps
28.9% 27.1% 31.1% Other income
+55.8% +58.0%
724 458 464 Net profit
+27.0% +6.8%
2,895 2,710 2,279 PAT margin %
+247 bps +37 bps
18.9% 18.5% 16.5% EPS (₹)
+27.4% +7.0%
12.10 11.31 9.50
Quality of profit
Pre-tax profit ₹4,099 Cr: core business ₹3,579 Cr, other income ₹724 Cr, exceptional & other items −₹204 Cr.
Core profit YoY: +1.5%
· reported profit +27.0%
Cash & debt
FY26 cash from operations ₹12,419 Cr:
108% of FY26 net profit of ₹11,488 Cr.
Borrowings ₹4,627 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹15,391 ₹15,300
-0.6% in line Net profit ₹2,495 ₹2,895
+16.0% above
AI read of the filing ₹15,180 Cr Q1 Revenue: Sun Pharma India Sales Grow 16%, Specialty Mix Hits 21.8% Positive Consolidated sales reached ₹15,180 crore, representing 10.1% YoY growth. India formulation sales grew 16% YoY to ₹5,474.9 crore, capturing 8.5% market share. US formulation sales fell 9.7% to $427 million, impacted by generic erosion including lenalidomide. Full analysis →
M Cap ₹16,283 Cr
P/E 27.0
PEG 3.38
Since results +20.7%
Profit +17% above its own trend Operating margin expanded 449 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+6.4% -7.1%
640 689 602 Operating profit
+23.1% -1.5%
212 215 172 OPM %
+449 bps +185 bps
33.1% 31.2% 28.6% Other income
+148.9% -2.6%
22.4 23.0 9.0 Net profit
+31.2% -1.8%
160 163 122 PAT margin %
+473 bps +134 bps
25.0% 23.7% 20.3% EPS (₹)
+31.6% -1.6%
13.04 13.25 9.91
Quality of profit
Pre-tax profit ₹212 Cr: core business ₹190 Cr, other income ₹22.4 Cr.
Core profit YoY: +23.3%
· reported profit +31.2%
Cash & debt
FY26 cash from operations ₹565 Cr:
100% of FY26 net profit of ₹565 Cr.
Borrowings ₹57.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹635 ₹640
+0.9% in line Net profit ₹137 ₹160
+16.8% above
AI read of the filing Alivus Q1 PAT Surges 31.7% YoY to ₹160.1 Cr; Revenue Grows 6.4% to ₹640.4 Cr Positive Net profit for Q1 FY27 rose to ₹160.08 cr, a 31.7% increase from ₹121.54 cr in Q1 FY26. Revenue from operations reached ₹640.41 cr, up 6.4% YoY from ₹601.85 cr. Total expenses were contained at ₹450.59 cr, representing only a 0.6% increase YoY. Full analysis →
M Cap ₹1,77,134 Cr
P/E 82.2
PEG 3.73
Since results -4.9%
Profit -16% below its own trend Operating margin expanded 134 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+54.8% +17.3%
4,921 4,197 3,178 Operating profit
+61.2% +22.7%
1,664 1,356 1,032 OPM %
+134 bps +151 bps
33.8% 32.3% 32.5% Other income
loss narrowed loss narrowed -12.0 -83.0 -37.0 Net profit
+3.3% +55.5%
566 364 548 PAT margin %
-574 bps +283 bps
11.5% 8.7% 17.2% EPS (₹)
-8.2% +38.2%
14.87 10.76 16.19
Quality of profit
Pre-tax profit ₹733 Cr: core business ₹766 Cr, other income −₹12.0 Cr, exceptional & other items −₹21.0 Cr.
Core profit YoY: -1.2%
· reported profit +3.3%
Cash & debt
FY26 cash from operations ₹3,023 Cr:
141% of FY26 net profit of ₹2,138 Cr.
Borrowings ₹15,026 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹3,685 ₹4,921
+33.6% above Net profit ₹674 ₹566
-16.1% below
AI read of the filing 55% Revenue Growth in Q1 FY27; JB Chemicals Consolidation Drives Performance Positive Consolidated Revenue reached ₹4,921 Cr, a 55% increase over Q1 FY26, including JB Chemicals' contribution. Operating EBITDA margin improved to 33.8% from 32.5% YoY, showing enhanced profitability in the base business. India business revenue grew 60% YoY to ₹2,890 Cr, with Torrent now ranked 1st in the Indian Cardiac market. Full analysis →
M Cap ₹97,830 Cr
P/E 47.3
PEG 2.78
Since results -7.3%
Profit +36% above its own trend Operating margin expanded 249 bps YoY Core business grew faster than reported profit (core profit +58%)
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+12.9% +17.1%
4,031 3,443 3,570 Operating profit
+24.7% +13.6%
1,056 930 847 OPM %
+249 bps -81 bps
26.2% 27.0% 23.7% Other income
-43.7% -52.1%
45.0 94.0 79.9 Net profit
+29.1% +2.7%
574 559 445 PAT margin %
+179 bps -199 bps
14.2% 16.2% 12.5% EPS (₹)
+29.6% +2.5%
13.76 13.43 10.62
Quality of profit
Pre-tax profit ₹769 Cr: core business ₹721 Cr, other income ₹45.0 Cr, exceptional & other items ₹3.9 Cr.
Core profit YoY: +57.5%
· reported profit +29.1%
Cash & debt
FY26 cash from operations ₹3,121 Cr:
161% of FY26 net profit of ₹1,938 Cr.
Borrowings ₹6,312 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹4,141 ₹4,031
-2.7% in line Net profit ₹421 ₹574
+36.3% above
AI read of the filing Mankind Pharma Q1 FY27 Standalone Revenue at ₹2,703 Cr; ₹1,250 Cr NCDs Redeemed Neutral Standalone revenue from operations for Q1 FY27 stood at ₹2,703.36 crore. Redeemed ₹1,250 crore worth of NCDs (ISIN INE634S07017) on April 16, 2026. Outstanding NCD debt remains at ₹3,788.51 crore across two remaining tranches. Full analysis →
M Cap ₹42,612 Cr
P/E 37.5
PEG 1.79
Since results +0.1%
Profit +11% above its own trend
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+24.8% +14.3%
1,626 1,422 1,303 Operating profit
+20.6% +27.2%
424 333 351 OPM %
-92 bps +263 bps
26.1% 23.4% 27.0% Other income
+169.3% +16.2%
70.9 61.0 26.3 Net profit
+30.9% +25.2%
334 267 255 PAT margin %
+95 bps +178 bps
20.6% 18.8% 19.6% EPS (₹)
+30.9% +25.3%
26.75 21.35 20.44
Quality of profit
Pre-tax profit ₹447 Cr: core business ₹376 Cr, other income ₹70.9 Cr.
Core profit YoY: +23.3%
· reported profit +30.9%
Cash & debt
FY26 cash from operations ₹529 Cr:
50% of FY26 net profit of ₹1,056 Cr.
Borrowings ₹260 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹1,524 ₹1,626
+6.7% above Net profit ₹301 ₹334
+10.9% above
AI read of the filing Q1 PAT up 31% to ₹334 Cr; ₹32/share Interim Dividend Announced Positive Revenue from operations increased 25% YoY to ₹1,626 cr, driven by US and India markets. Profit After Tax (PAT) grew 31% YoY to ₹334 cr with a healthy 21% net margin. Declared 1st interim dividend of ₹32 per share on a face value of ₹2, totaling ₹400 cr. Full analysis →
M Cap ₹1,494 Cr
P/E —
PEG —
Since results +85.8%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
— —
87.6 — — Operating profit
— —
15.6 — — OPM %
— —
17.8% — — Other income
— —
0.1 — — Net profit
— —
8.3 — — PAT margin %
— —
9.5% — — EPS (₹)
— —
0.16 — —
Quality of profit
Pre-tax profit ₹13.7 Cr: core business ₹13.6 Cr, other income ₹0.1 Cr.
Core profit YoY: —
AI read of the filing AHCL Q1 PAT Grows 35% YoY to ₹4.8 Cr; Board Approves Subsidiary Acquisitions via Share Swap Neutral Net Profit increased to ₹4.80 Cr in Q1 FY27 from ₹3.55 Cr in Q1 FY26, a growth of 35.2%. Revenue from operations fell to ₹30.98 Cr in Q1 FY27 from ₹33.30 Cr in the year-ago period. Board approved share swap to acquire 32.52% of Apiqo Organics and 43.33% of Bizotic LifeScience. Full analysis →
M Cap ₹26,087 Cr
P/E 105.6
PEG —
Since results +0.1%
Into loss: a profit a year ago Profit -157% below its own trend Operating margin expanded 307 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+17.4% -17.5%
2,270 2,752 1,934 Operating profit
+82.4% -57.6%
195 461 107 OPM %
+307 bps -814 bps
8.6% 16.7% 5.5% Other income
+11.2% from loss 109 -116 98.0 Net profit
to loss loss widened -69.4 -8.8 113 PAT margin %
-891 bps -274 bps
-3.1% -0.3% 5.9% EPS (₹)
loss narrowed loss widened -0.52 -0.07 -0.61
Quality of profit
Pre-tax profit −₹7.5 Cr: core business −₹116 Cr, other income ₹109 Cr.
Core profit YoY: loss narrowed
Cash & debt
FY26 cash from operations ₹1,653 Cr:
385% of FY26 net profit of ₹430 Cr.
Borrowings ₹5,675 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹1,897 ₹2,270
+19.6% above Net profit ₹123 −₹69.4
-156.5% below
AI read of the filing PPLPHARMA Q1 Standalone Revenue Up 16% YoY to ‣1,125 Cr; Net Profit Flat at ‣113 Cr Neutral Standalone revenue from operations increased 16% YoY to ‣1,124.95 Cr. Standalone net profit after tax remained flat at ‣113.48 Cr (EPS of ‣0.85). Finance costs decreased by 29.6% YoY to ‣16.36 Cr from ‣23.23 Cr. Full analysis →
M Cap ₹16,224 Cr
P/E 24.4
PEG 1.28
Since results -15.7%
Profit -18% below its own trend Operating margin contracted 188 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+13.0% +15.4%
873 757 773 Operating profit
+7.1% +8.9%
296 272 277 OPM %
-188 bps -201 bps
33.9% 35.9% 35.8% Other income
-11.2% +19.5%
2.4 2.0 2.7 Net profit
+14.6% -48.6%
143 279 125 PAT margin %
+23 bps -2044 bps
16.4% 36.9% 16.2% EPS (₹)
+18.7% -49.4%
10.28 20.33 8.66
Quality of profit
Pre-tax profit ₹179 Cr: core business ₹178 Cr, other income ₹2.4 Cr.
Core profit YoY: +12.7%
· reported profit +14.6%
Cash & debt
FY26 cash from operations ₹538 Cr:
83% of FY26 net profit of ₹647 Cr.
Borrowings ₹2,359 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹830 ₹873
+5.2% above Net profit ₹175 ₹143
-18.0% below
AI read of the filing ₹3,130 Cr TTM Revenue Base: Eris Lifesciences Approves Q1 FY27 Results with Clean Audit Report Neutral Board meeting conducted over 1.5 hours from 11:30 AM to 1:00 PM on July 29, 2026. Unmodified audit opinion received for both standalone and consolidated results. Re-appointment of Cost Auditors for the 2026-27 financial year approved. Full analysis →
M Cap ₹4,497 Cr
P/E 37.5
PEG —
Since results -2.7%
Profit +134% above its own trend Operating margin expanded 112 bps YoY FY26 operating cash flow was only 49% of profit
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+15.8% +10.6%
196 177 169 Operating profit
+22.0% +31.2%
43.3 33.0 35.5 OPM %
+112 bps +348 bps
22.1% 18.6% 21.0% Other income
-10.1% -66.4%
4.7 14.0 5.2 Net profit
+17.0% +2.5%
30.8 30.0 26.3 PAT margin %
+16 bps -123 bps
15.7% 16.9% 15.6% EPS (₹)
+17.0% +2.9%
18.60 18.08 15.90
Quality of profit
Pre-tax profit ₹41.5 Cr: core business ₹36.8 Cr, other income ₹4.7 Cr.
Core profit YoY: +21.7%
· reported profit +17.0%
Cash & debt
FY26 cash from operations ₹56.0 Cr:
49% of FY26 net profit of ₹115 Cr.
Borrowings ₹20.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹192 ₹196
+1.7% in line Net profit ₹13.1 ₹30.8
+134.0% above
AI read of the filing RPG Life Sciences Q1 FY27: PAT up 17% YoY to ₹30.76 Cr on 15.8% Revenue Growth Positive Consolidated Revenue from Operations increased 15.8% YoY to ₹195.69 Cr from ₹168.92 Cr. Net Profit (PAT) grew 17% YoY to ₹30.76 Cr, up from ₹26.29 Cr in Q1 FY26. Earnings Per Share (EPS) for the quarter rose to ₹18.60 from ₹15.90 YoY. Full analysis →
M Cap ₹8,261 Cr
P/E 31.1
PEG —
Since results -22.3%
Profit -21% below its own trend Operating margin expanded 621 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+6.7% +2.9%
236 229 221 Operating profit
+27.6% +0.3%
89.3 89.0 70.0 OPM %
+621 bps -98 bps
37.9% 38.9% 31.7% Other income
-47.5% +5.0%
6.3 6.0 12.0 Net profit
+12.8% +1.2%
68.8 68.0 61.0 PAT margin %
+159 bps -50 bps
29.2% 29.7% 27.6% EPS (₹)
+13.3% +1.5%
29.87 29.44 26.36
Quality of profit
Pre-tax profit ₹91.9 Cr: core business ₹85.6 Cr, other income ₹6.3 Cr.
Core profit YoY: +27.8%
· reported profit +12.8%
Against its own trend ?
Trend Actual Gap
Sales ₹308 ₹236
-23.6% below Net profit ₹87.2 ₹68.8
-21.1% below
AI read of the filing 13% Net Profit Growth in Q2 2026; Domestic Sales Up 12% YoY on Product Relaunches Positive Revenue from operations grew 7% YoY to ₹235.7 Cr in Q2 2026. Domestic sales increased by 12% YoY, aided by the re-establishment of key brands in the market. Profit Before Tax (PBT) reached ₹91.9 Cr, a 16% increase over the same quarter last year. Full analysis →
M Cap ₹2,126 Cr
P/E 658.3
PEG —
Since results -7.5%
Turnaround: profit against a loss a year ago Operating margin expanded 452 bps YoY All of pre-tax profit came from other income or one-off items Exceptional items of ₹97.3 Cr in the quarter
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+6.5% -2.1%
466 476 438 Operating profit
+126.7% -20.5%
39.7 50.0 17.5 OPM %
+452 bps -198 bps
8.5% 10.5% 4.0% Other income
+112.3% -13.5%
3.5 4.0 1.6 Net profit
from loss from loss 65.4 -24.0 -36.4 PAT margin %
+2234 bps +1908 bps
14.0% -5.0% -8.3% EPS (₹)
from loss from loss 7.09 -2.34 -3.94
Quality of profit
Pre-tax profit ₹77.7 Cr: core business −₹23.1 Cr, other income ₹3.5 Cr, exceptional & other items ₹97.3 Cr.
Core profit YoY: loss narrowed
Cash & debt
FY26 cash from operations ₹192 Cr.
Borrowings ₹1,090 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹483 ₹466
-3.4% in line
AI read of the filing Indoco Remedies Q1 Net Profit at ₹82.32 Cr, Driven by ₹97.34 Cr Ophthalmic Business Sale Positive Net Profit of ₹82.32 Cr vs a loss of ₹28.07 Cr in the previous year's corresponding quarter Exceptional gain of ₹97.34 Cr recognized from the completed sale of the Ophthalmic Business Division EBITDA margin expanded to 10.3% (₹42.2 Cr) from 3.8% (₹14.8 Cr) in Q1 FY26 Full analysis →
M Cap ₹6,079 Cr
P/E 46.4
PEG 0.33
Since results -4.3%
Profit -28% below its own trend Operating margin expanded 508 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+30.6% +3.0%
180 175 138 Operating profit
+57.4% +14.4%
53.8 47.0 34.2 OPM %
+508 bps +297 bps
29.8% 26.9% 24.8% Other income
-16.4% -79.9%
2.8 14.0 3.4 Net profit
+43.8% -17.7%
30.4 37.0 21.2 PAT margin %
+155 bps -425 bps
16.9% 21.1% 15.3% EPS (₹)
+43.7% -3.6%
6.61 6.86 4.60
Quality of profit
Pre-tax profit ₹39.5 Cr: core business ₹36.6 Cr, other income ₹2.8 Cr.
Core profit YoY: +58.5%
· reported profit +43.8%
Cash & debt
FY26 cash from operations ₹62.0 Cr:
51% of FY26 net profit of ₹122 Cr.
Borrowings ₹342 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹227 ₹180
-20.8% below Net profit ₹42.4 ₹30.4
-28.1% below
AI read of the filing Rs 180.21 Cr Revenue: Senores Pharma Reports 36% YoY Growth in Q1 FY27; PAT at Rs 30.45 Cr Neutral Revenue from operations grew 35.9% YoY to Rs 180.21 Cr from Rs 132.56 Cr in the year-ago quarter. Net Profit for Q1 FY27 stood at Rs 30.45 Cr, representing a 43.8% increase over Q1 FY26. Sequential revenue growth was modest at 2.9% compared to Rs 175.19 Cr in Q4 FY26. Full analysis →
M Cap ₹1,10,040 Cr
P/E 100.9
PEG 25.23
Since results +30.4%
Profit +12% above its own trend Operating margin expanded 715 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+29.1% +11.8%
2,026 1,812 1,570 Operating profit
+67.0% +24.7%
638 512 382 OPM %
+715 bps +324 bps
31.5% 28.3% 24.3% Other income
-12.0% -23.5%
9.2 12.0 10.4 Net profit
+123.9% +28.4%
362 282 162 PAT margin %
+756 bps +230 bps
17.9% 15.6% 10.3% EPS (₹)
+125.5% +31.7%
6.81 5.17 3.02
Quality of profit
Pre-tax profit ₹481 Cr: core business ₹472 Cr, other income ₹9.2 Cr.
Core profit YoY: +120.9%
· reported profit +123.9%
Cash & debt
FY26 cash from operations ₹1,624 Cr:
182% of FY26 net profit of ₹890 Cr.
Borrowings ₹2,518 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹2,017 ₹2,026
+0.5% in line Net profit ₹323 ₹362
+11.9% above
AI read of the filing Laurus Labs Q1 Net Profit Jumps 124% YoY to ₹362 Cr; Revenue Up 29% Positive Consolidated revenue from operations increased 29.1% YoY to ₹2,026.31 Cr from ₹1,569.57 Cr. Net profit after tax surged 124% YoY to ₹362.07 Cr compared to ₹161.68 Cr in Q1 FY26. Earnings Per Share (EPS) rose to ₹6.81 from ₹3.02 in the corresponding quarter of the previous year. Full analysis →
M Cap ₹25,876 Cr
P/E 66.9
PEG —
Since results -8.3%
Profit -15% below its own trend Operating margin expanded 973 bps YoY Core business grew faster than reported profit (core profit +142%)
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+59.1% -23.9%
330 433 207 Operating profit
+122.1% -38.5%
113 184 50.9 OPM %
+973 bps -820 bps
34.3% 42.5% 24.6% Other income
-88.7% -83.6%
1.8 11.0 15.9 Net profit
+70.4% -44.0%
75.0 134 44.0 PAT margin %
+151 bps -820 bps
22.7% 30.9% 21.2% EPS (₹)
+67.7% -43.6%
9.07 16.09 5.41
Quality of profit
Pre-tax profit ₹104 Cr: core business ₹102 Cr, other income ₹1.8 Cr.
Core profit YoY: +142.3%
· reported profit +70.4%
Against its own trend ?
Trend Actual Gap
Sales ₹274 ₹330
+20.3% above Net profit ₹88.0 ₹75.0
-14.8% below
AI read of the filing Q1 Revenue up 59% YoY to ₹329.7 Cr; PAT rises 70% to ₹75 Cr Positive Consolidated revenue from operations grew 59% YoY to ₹329.67 Cr from ₹207.24 Cr. Net profit for the quarter stood at ₹75.00 Cr, a 70% increase over the ₹44.01 Cr reported in June 2025. Basic EPS improved to ₹9.07 compared to ₹5.41 in the year-ago period. Full analysis →
How to read this page
The numbers. Each card is one company's Q1 FY27 results as filed with NSE or BSE, read from the
filing within hours of its release, in ₹ crore. We show the consolidated statement, or the standalone one when
the consolidated figures are a copy of it or have no year-ago quarter to compare with. YoY compares with the same
quarter a year earlier and QoQ with the quarter before (the previous half-year for companies that report every six months).
A swing between profit and loss is described in words: a percentage across it would mislead.
Margins. Operating margin (OPM) is operating profit, before depreciation, interest and other income,
as a share of sales; PAT margin is net profit as a share of sales. Their changes are in basis points
(100 bps = 1 percentage point).
Quality of profit. Core profit is operating profit minus interest and depreciation: what the business
itself earned before tax. The rest of pre-tax profit is other income (interest on cash, dividends, gains on
investments) and exceptional or one-off items. We flag a quarter when that share is 25% or more,
and when reported profit grew much faster than core profit. For banks we compare pre-provision profit with net
profit, since a fall in provisions can lift profit without the business growing.
Against its own trend. We do not have analyst consensus estimates, and we do not make them up. Instead
each company is measured against the path it was on: the same quarter last year, grown at the median of its
last four year-on-year growth rates (held between −50% and +100%; at least two growth rates needed). Sales
5% or more above that, or net profit 10% or more above, is "above trend";
as far below is "below trend". It answers "was this quarter better or worse than the company's own recent
run?", which consensus does not.
Cash and debt. Profit is an accounting figure; cash is harder to dress up. For each company we show
its operating cash flow for the last financial year as a share of that year's net profit (flagged under
50%, or when it is negative despite a profit), and its borrowings at the latest balance sheet
against the one six months earlier (flagged at a 25% move). Balance sheets come with the
September and March results, cash-flow statements with the March results.
Price since results. The latest close against the last close before the filing (a filing after 3:30 pm
counts from the next session). It is a fact about the market's reaction, not advice.
Market cap groups. Large cap is the 100 largest companies by market value and mid cap the next 150
(SEBI's ranking); below that, small cap is ₹5,000 Cr or more, micro cap ₹500 Cr or more, nano cap below.
Data source Quarterly results filed by listed companies with NSE and BSE (Regulation 33 of SEBI LODR), read from each filing; share prices from the exchanges; market cap and P/E from our daily fundamentals snapshot.
Last updated 12 Oct 2026, 13:17 IST
